Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Spezifität
This STEAP1 antibody does not cross-react with other STEAP proteins.
Aufreinigung
STEAP1 Antibody is affinity chromatography purified via peptide column.
Immunogen
STEAP1 antibody was raised against a 18 amino acid synthetic peptide from near the carboxy terminus of human STEAP1. The immunogen is located within the last 50 amino acids of STEAP1.
STEAP1 antibody can be used for detection of STEAP1 by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
STEAP1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
STEAP1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
STEAP1
(Six Transmembrane Epithelial Antigen of The Prostate 1 (STEAP1))
PRSS24 antikoerper, STEAP antikoerper, STEAP1 antikoerper, 2410007B19Rik antikoerper, Prss24 antikoerper, Steap antikoerper, STEAP family member 1 antikoerper, six transmembrane epithelial antigen of the prostate 1 antikoerper, STEAP1 antikoerper, Steap1 antikoerper
Hintergrund
STEAP1 Antibody: The six-transmembrane epithelial antigen of prostate 1 (STEAP1) was the first member of a family of metalloreductases identified as cell-surface antigens in prostate tissue. The normal function of STEAP is still uncertain, unlike other members of the STEAP family, STEAP1 does not promote iron or copper reduction or uptake and lacks the FNO-like reductase domain critical for activity. However, its expression is highly increased in multiple cancer cell lines, including prostate, bladder, colon, and ovarian cancers. Supporting this is evidence that STEAP1 peptides can be used to stimulate CD8+ T cells from healthy donors, enabling them to recognize STEAP1-positive human tumor cells, suggesting that STEAP1 may a potential target for cancer immunotherapy. At least three isoforms of STEAP1 are known to exist.